Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The first product launch from start-up Hurley Research ... What sets Droidles completely apart from other stand alone ... to communicate, share code with each other and evolve ... invention is the system,” said Hurley Research founder Jay ... their own, both physically and on the internet." Remote ...
(Date:7/29/2014)... FL (PRWEB) July 29, 2014 EXpressLO ... situ lift out specimen preparation solutions, has been granted ... Office for specimen manipulation methods incorporating a unique specimen ... This is the second company patent for EXpressLO ... Giannuzzi. , These complementary patents extend EXpressLO’s ...
(Date:7/28/2014)... July 28, 2014 “2014 ... Lubricant Industry” is a professional and in-depth ... market. The report introduces Lubricant basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
(Date:7/28/2014)... According to the ... Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, Environmental, ... - Global Forecasts to 2019" published by ... at $896.5 Million in 2014 and is ... growing at a CAGR of 5.9% from ...
Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... 2012 Oxford BioTherapeutics (OBT) today announces that ... advisor and non-executive director.  Dr Begley, who was the Vice ... Amgen, will take on a key role in helping shape ... its pipeline of oncology antibody-based drugs into clinical development. ...
... Advanstar Communications, is pleased to announce the agenda for ... held April 26 - 27, 2012 at the Loews ... share their strategies for improving patient outcomes and product ... Conference highlights include: , The ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 2Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 3Complete Agenda Announced for 11th Annual Patient Adherence Forum 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
(Date:7/28/2014)... Yale School of Medicine have pinpointed a mechanism in part ... in the blood, linking it to both type 1 and ... 28 issue of Proceedings of the National Academies of ... enzyme located in a part of the hypothalamus known ... in motion that control glucose levels in the blood," said ...
(Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Glucose 'control switch' in the brain key to both types of diabetes 2Strategies identified to improve oral contraceptive success with obese women 2
... developed a clever method to purify parasitic organisms from ... proteomic studies and a deeper insight into the biology ... each year. Many infectious pathogens, like those ... have a complex life cycle alternating between free-living creature ...
... carbon dioxide from burning of fossil fuels might be kept below ... next few decades, say researchers. They say that less plentiful oil ... greater supplies of coal mean that it must be the main ... Biogeochemical Cycles . , ...
... addition to social factors when selecting a mate. In ... PLoS Genetics, scientists in China, France, and the ... be involved in mate choice in some human populations. ... Major Histocompatibility Complex (MHC), a large genomic region involved in ...
Cached Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3
See product name for description....
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
Biology Products: